Ro vs Henry Meds: Comparing GLP-1 Telehealth (2026)

Disclosure: Vital Signs Today may earn a commission if you buy through links on this page, at no extra cost to you. This does not influence our evidence-based assessments. We are not a medical provider; talk to a clinician before acting on test results.

Quick answer: Ro and Henry Meds both put a GLP-1 prescription within reach through a phone screen, but they are not the same product. Ro routes you to brand-name, FDA-approved drugs like Wegovy and Zepbound, with an insurance concierge that tries to get the medication covered. Henry Meds built its business on compounded semaglutide and tirzepatide sold at a flat cash price. That distinction got far more important in 2026, because the FDA shortage that made broad compounding legal has ended. Read on for the honest trade-offs, current pricing, and who each one actually fits.

Disclosure: Vital Signs Today may earn a commission if you buy through links on this page, at no extra cost to you. This does not influence our evidence-based assessments. We are not a medical provider; talk to a clinician before acting on test results.

The verdict in 30 seconds

If you want the same medication your endocrinologist would write, a real shot at insurance coverage, and a program that escalates your dose under supervision, Ro is the stronger pick. You pay a membership on top of the drug, but you get the FDA-approved version and a team that fights your insurer.

If you have no coverage, you want one flat monthly bill, and you accept a compounded medication, Henry Meds is built for that. The catch in 2026 is that the legal ground under compounded GLP-1s has shifted. The federal shortage that allowed pharmacies to mass-produce these drugs is over, so what used to be a wide-open lane is now a narrow exception.

And if neither extreme fits, there is a middle option we walk through at the end.

Brand vs compounded GLP-1 in 2026 (why it matters now)

This is the single most important thing to understand before you compare prices, so we are putting it first.

A “brand” GLP-1 is the manufactured product: Wegovy and Ozempic (semaglutide, made by Novo Nordisk), Zepbound and Mounjaro (tirzepatide, made by Eli Lilly). These are FDA-approved. Every batch is made in a regulated facility, tested for potency and purity, and carries an approved label. Ro dispenses these.

A “compounded” GLP-1 is a copy mixed by a compounding pharmacy. Compounding is legal in specific situations, and one of those situations is a national drug shortage. When Wegovy and Zepbound were impossible to find in 2023 and 2024, the FDA allowed compounders to fill the gap. That is the era Henry Meds and dozens of other cash-pay telehealth brands grew up in.

That era has closed. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. Once a drug comes off the shortage list, the legal cover for mass compounding goes with it. The agency set hard deadlines: 503A pharmacies had to stop compounding semaglutide by April 22, 2025, and tirzepatide by February 19, 2025; the larger 503B outsourcing facilities had even earlier dates. (Sources: FDA, Drug Topics.)

In April 2026, the FDA went further and proposed leaving semaglutide, tirzepatide, and liraglutide off the 503B bulks list permanently, saying there is no clinical need for outsourcing facilities to keep compounding them from bulk powder. The public comment window ran through late June 2026. (Source: FDA press announcement.)

So is compounded GLP-1 simply illegal now? Not entirely, and this is where honest reporting matters. A smaller category of compounding, called 503A patient-specific compounding, can still happen. A licensed pharmacy can compound a drug for an individual patient when there is a documented clinical reason the FDA-approved version does not work for that person, for example a genuine allergy to an inactive ingredient or a need for a dose that is not commercially made. What is gone is the version most cash-pay sites relied on: producing standardized compounded vials in volume for anyone who passes a quick screen. The FDA has been sending warning letters to pharmacies and telemedicine practices that blur the line. (Source: GoodRx.)

Why should a buyer care? Three reasons. First, supply: a model built on broad compounding is now standing on a narrowing legal exception, which creates real uncertainty about whether your refill keeps coming. Second, oversight: compounded products are not FDA-approved, are not checked batch by batch the way manufactured drugs are, and have generated safety reports. As of early 2025 the FDA had logged more than 455 adverse event reports tied to compounded semaglutide and more than 320 tied to compounded tirzepatide, many from dosing errors when patients drew the wrong amount from multidose vials, some serious enough to require hospitalization. (Source: FDA.) Third, insurance: compounded drugs are never covered, so the “cheap” cash price is the whole price, with no path to a copay.

None of this makes compounded medication automatically dangerous or every cash-pay provider a bad actor. It does mean the headline price is no longer the only number that matters. You are also buying a level of regulatory certainty, and in 2026 brand and compounded sit on opposite ends of that scale.

Ro in depth

Ro (ro.co) is one of the older direct-to-consumer telehealth companies in the United States. Its weight program, marketed as the Ro Body membership, is built around brand-name GLP-1 medication rather than compounded copies.

What you actually get

You complete an online intake, a licensed provider reviews it, and if you qualify, they can prescribe an FDA-approved GLP-1: Wegovy or Ozempic (semaglutide), or Zepbound or Mounjaro (tirzepatide). The membership wraps a few services around that prescription: provider messaging, dose management as you titrate up, and an insurance concierge whose job is to push your plan to cover the drug. (Sources: Ro, Medical News Today.)

Pricing

Ro splits the bill into two parts, which trips up a lot of shoppers. The membership is one line. The medication is another.

• Membership: $39 for the first month, then $149 per month on a monthly plan, dropping to about $74 per month if you prepay for a year.
• Medication, cash price: new patients can start the Wegovy pill or an oral option around $149 per month. The Wegovy pen has been promoted at $199 per month for the first two months, then about $349 per month afterward. Zepbound vials start around $299 per month. Prepaying annually unlocks the lowest medication tiers.
• Medication, with insurance: if Ro’s concierge gets your plan to cover the drug, your medication cost can fall to just a copay. That is the scenario where Ro becomes dramatically cheaper than any cash-pay compounder.

(Source: Ro pricing page.) Note one limit: insurance does not cover the membership itself, and Ro cannot coordinate government-plan coverage, so Medicare, Medicare Supplement, and TRICARE members can join but pay cash for the medication, while most Medicaid members cannot enroll.

Eligibility

Ro screens against the standard clinical criteria for GLP-1 weight management: a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnea, or cardiovascular disease. A provider, not a sales page, signs off. (Source: Medical News Today.)

Strengths and weaknesses

The strengths are the FDA-approved medication, the genuine insurance pursuit, and structured dose escalation. The weakness is cost transparency at the start: because the drug is billed separately and the cash price for a pen can land near $349 per month on top of the $149 membership, the all-in monthly number can exceed a flat-rate compounder, unless insurance kicks in. If your plan covers the drug, Ro usually wins on price and on safety. If it does not, Ro can be the more expensive route.

Henry Meds in depth

Henry Meds is a cash-pay telehealth brand that scaled during the shortage years by offering compounded GLP-1 at a flat monthly price with no separate membership fee.

What you actually get

The pitch is simplicity: one price that bundles the medication, supplies, shipping, and provider visits. You do an online evaluation, a provider reviews it, and if approved you receive compounded semaglutide or tirzepatide (or other options like compounded liraglutide, oral versions, or phentermine). All of Henry’s GLP-1 products are compounded, not brand-name, which means none of them are eligible for insurance coverage. (Source: GLP-1.com provider review.)

Pricing

Henry advertises an entry price as low as $179 per month, but that figure applies to compounded liraglutide or to long commitments, not to the injectable semaglutide most people picture. The real numbers, billed monthly:

• Compounded semaglutide injection: roughly $297 per month at a standard dose month-to-month, with bundle pricing dropping to about $247 on a 6-month plan and $197 on a 12-month plan. Higher doses can add $100 per month.
• Oral semaglutide: about $249 to $349 per month.
• Oral tirzepatide: about $349 to $449 per month. Injectable tirzepatide runs higher.
• Compounded liraglutide: around $179 per month. Phentermine around $149 per month.

(Sources: GLP-1.com, Henry Meds review.) The big appeal is that this is one number with no insurance paperwork. The catch is that the cheapest prices require committing to a multi-month bulk order, and bulk and prepaid orders are non-refundable.

Eligibility

Henry uses the same general medical framework, an evaluation with a licensed provider and the standard BMI thresholds (30 or higher, or 27 or higher with a weight-related condition), though the company publishes less detail about its screening than Ro does. Treat any program that approves you in minutes with skepticism; a real clinical review takes more than a checkbox.

Strengths and weaknesses

The strength is price predictability for someone with no coverage: one flat bill, medication included. The weaknesses are real and worth naming. Proactive patient check-ins are thin compared with programs that include coaching. Multiple Better Business Bureau complaints report continued billing after a customer tried to cancel, so cancellation is not always as clean as the month-to-month framing suggests. And the entire model rests on compounded medication, which in 2026 means a non-FDA-approved product on shifting legal ground. (Source: GLP-1.com.)

Head to head

Drug type

Ro: brand-name, FDA-approved semaglutide and tirzepatide. Henry: compounded copies. This is the deciding axis in 2026. Brand means regulated manufacturing, batch testing, an approved label, and insurance eligibility. Compounded means a pharmacy-mixed product that is not FDA-approved, cannot be covered, and now depends on a narrow patient-specific compounding exception rather than the expired shortage allowance.

Price

On sticker price for cash payers, Henry can look cheaper, especially on a 12-month bulk plan around $197 per month all-in. Ro’s all-in cash cost (membership plus a brand pen) can sit higher. But the comparison flips the moment insurance enters. Ro is the only one of the two that can get your medication covered, and a covered Wegovy or Zepbound prescription can cost less than any compounded plan. So the right way to read price is: no coverage and unwilling to chase it, Henry is cheaper; any chance of coverage, Ro can win outright.

What is included

Henry bundles everything into one price with no separate membership. Ro separates the membership from the medication and adds an insurance concierge. Henry is simpler to read on a single invoice; Ro does more on your behalf with insurers and dose management.

Support and cancellation

Ro offers structured titration and provider messaging. Henry’s proactive outreach is lighter, and its cancellation has drawn BBB billing complaints, while bulk prepaid orders are non-refundable. If you value being able to stop cleanly, read Henry’s terms before you prepay for six or twelve months.

Risk

Brand medication through Ro carries the normal GLP-1 side-effect profile but not the added compounding risks. Compounded medication through Henry carries that same drug-class side-effect profile plus the extra layer tied to compounding: no FDA approval, no batch-level verification, and the documented dosing-error reports the FDA has flagged. For a YMYL decision about a drug you inject weekly, that extra layer is not a footnote.

Who should pick which

Pick Ro if: you have insurance that might cover a GLP-1 and want someone to fight for that coverage; you want the exact FDA-approved medication; you want supervised dose escalation; or you simply are not comfortable with a non-approved compounded product given the 2026 legal picture.

Pick Henry Meds if: you have no realistic path to coverage, you want one flat predictable bill, you have weighed the compounding trade-offs with eyes open, and you have read the cancellation terms before committing to a bulk plan.

Pick neither, yet, if: you have not confirmed you are clinically eligible, you have a personal or family history of medullary thyroid cancer or MEN2, or you are pregnant or planning pregnancy. In those cases the first move is a conversation with a clinician, not a checkout page.

A safer-footing alternative

The Ro-versus-Henry choice forces a hard trade: pay more for brand and coverage, or pay a flat rate for a compounded product whose legal status is contracting. Plenty of readers want a middle path, a telehealth program that is straightforward on price without leaning entirely on the compounding exception.

That is where it pays to look at Hundred, a telehealth option we track alongside Ro and Henry. It is worth comparing on the same terms we used above: drug type, total monthly cost, what the price includes, and how clean the cancellation is.

Do not stop at three names, though. The right provider depends on your insurance, your starting BMI, and how much hand-holding you want. For the complete picture, read our full ranking: see our full ranking of GLP-1 telehealth providers.

How GLP-1 works, results, side effects, and who should avoid it

GLP-1 medications mimic a gut hormone, glucagon-like peptide-1, that the body releases after eating. They slow how fast the stomach empties, signal fullness to the brain, and steady blood sugar. The practical result is that you eat less without white-knuckling it. Tirzepatide adds a second hormone target (GIP), which is part of why it tends to produce more weight loss than semaglutide.

Results. In clinical trials, semaglutide produced about 12% placebo-corrected weight loss and tirzepatide about 18%. (Source: PMC review.) Real-world numbers vary with dose, adherence, diet, and activity, and weight tends to return if the medication stops without lifestyle changes in place.

Side effects. The common ones are gastrointestinal: nausea, vomiting, diarrhea, and constipation. In one trial, about 44% of semaglutide patients reported nausea and roughly 25% reported vomiting, mostly mild to moderate and concentrated in the first 20 weeks as the dose climbs. Slower titration usually helps. (Source: PMC review.)

Serious risks. These drugs carry a boxed warning and are not recommended for anyone with a personal or family history of medullary thyroid carcinoma or MEN2. Pancreatitis is a known risk, and patients with existing diabetic retinopathy should consult an eye doctor before starting, because rapid blood-sugar improvement can temporarily worsen it. (Source: PCOM.)

Who should avoid it. People with the thyroid-cancer history above, those who are pregnant or trying to conceive, and anyone whose provider flags a conflicting condition or medication. This is exactly why the brand-versus-compounded question is not just about price: the strength of the clinical review you get matters as much as the molecule. This article is evidence-based information, not medical advice; a licensed provider makes the call for your situation.

Frequently asked questions

Is Ro or Henry Meds cheaper?

For a cash payer with no coverage, Henry Meds usually has the lower sticker price, around $197 per month all-in on a 12-month compounded semaglutide plan, versus Ro’s $149 membership plus a brand medication that can run near $349 per month. But if Ro’s insurance concierge gets your plan to cover the drug, Ro can cost far less, sometimes just a copay. The real answer depends on your insurance.

Does Ro use brand or compounded GLP-1?

Ro prescribes brand-name, FDA-approved GLP-1 medications: Wegovy and Ozempic (semaglutide) and Zepbound and Mounjaro (tirzepatide). It does not build its program on compounded copies.

Is Henry Meds legit and safe in 2026?

Henry Meds is a real telehealth company that connects you with licensed providers. The caution is the product: its GLP-1 options are compounded, which means not FDA-approved and not insurance-eligible, and broad compounding now rests on a narrow legal exception after the FDA shortage ended. Compounded GLP-1 has also generated FDA adverse-event reports. Safe is not a yes-or-no answer here; it depends on the medication type and your own health profile.

Are compounded GLP-1s still legal in 2026?

Mass compounding under the shortage allowance is over; the FDA declared the semaglutide and tirzepatide shortages resolved in early 2025 and set deadlines to stop. A narrower form, 503A patient-specific compounding for a documented individual clinical need, can still occur, but the FDA has proposed permanently barring these drugs from the 503B bulks list and has warned pharmacies that overstep. Expect tighter availability for cash-pay compounded programs.

Will insurance cover Ro or Henry Meds?

Insurance can cover the brand medication Ro prescribes, and Ro’s concierge actively pursues that, though insurance never covers the Ro membership itself. Henry Meds uses compounded drugs, which insurance does not cover under any plan, so its price is always out of pocket.

What BMI do I need to qualify?

Both programs follow the standard clinical criteria: a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea. A licensed provider confirms eligibility.

How much weight can I expect to lose on a GLP-1?

Trial averages were about 12% placebo-corrected weight loss for semaglutide and about 18% for tirzepatide. Your result depends on dose, how consistently you take it, and the diet and activity habits you build alongside it. Weight commonly returns if the medication stops without those habits in place.

What are the most common side effects?

Nausea, vomiting, diarrhea, and constipation are the most common, usually mild to moderate and worst in the first few months as the dose increases. Serious but rarer risks include pancreatitis, and the drugs are not recommended for people with a personal or family history of medullary thyroid cancer or MEN2.

Can I cancel either program easily?

Ro is a monthly membership you can stop through your account. Henry Meds offers month-to-month cancellation too, but its bulk and prepaid plans are non-refundable, and the Better Business Bureau has logged complaints about billing continuing after cancellation. Read the terms before prepaying for multiple months.

Which is better for someone with insurance?

Ro, clearly. It prescribes the brand medication insurers can cover and actively works to secure that coverage, which can drop your cost to a copay. Henry Meds cannot use insurance at all because its products are compounded.